← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Tria Bioscience Corporation
Seattle, WA
$12,422,906
Total funding
9
Grants
Funding over time
peak $1.8M · FY2009–20$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$12,197,940 · 8
CDC$224,966 · 1
By mechanism
UH3$4,110,456 · 1
R43$3,113,634 · 6
R44$3,000,000 · 1
UH2$2,198,816 · 1
Investigators at Tria Bioscience Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical development of a TriCoil-based nicotine vaccine$1,379,921
UH3 · FY2018 · DA
Preclinical development of a TriCoil-based nicotine vaccine$1,365,834
UH3 · FY2019 · DA
Preclinical development of a TriCoil-based nicotine vaccine$1,364,701
UH3 · FY2020 · DA
Preclinical development of a TriCoil-based nicotine vaccine$1,174,182
UH2 · FY2015 · DA
Preclinical development of a TriCoil-based nicotine vaccine$1,024,634
UH2 · FY2016 · DA
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.$1,000,000
R44 · FY2012 · AI
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.$1,000,000
R44 · FY2013 · AI
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.$1,000,000
R44 · FY2011 · AI
Pandemic H5N1 vaccine containing recombinant H5 and a synthetic TLR4 agonist, GLA$440,220
R43 · FY2009 · AI
Pandemic H5N1 vaccine containing recombinant H5 and a synthetic TLR4 agonist, GLA$316,224
R43 · FY2010 · AI
Cross-Protective Monoclonal Antibodies for treatment of pandemic Flu$300,000
R43 · FY2012 · AI
A novel DC-targeting non-integrating lentivector vaccine for HIV infection$300,000
R43 · FY2011 · AI
Cross-Protective Monoclonal Antibodies for treatment of pandemic Flu$300,000
R43 · FY2013 · AI
A novel DC-targeting non-integrating lentivector vaccine for HIV infection$300,000
R43 · FY2010 · AI
Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients$298,747
R43 · FY2013 · AI
Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients$280,636
R43 · FY2014 · AI
Synthetic Universal Flu Vaccine$224,966
R43 · FY2018 · IP
Advanced Design of a Nicotine Vaccine for Smoking Cessation$201,390
R43 · FY2013 · DA
Advanced Design of a Nicotine Vaccine for Smoking Cessation$151,451
R43 · FY2012 · DA